SCHEMBL34229

SCHEMBL34229

O=C(CCCCCS)C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 13/20 0.51
HDAC2 Q92769 12/20 0.51
HDAC3 O15379 12/20 0.51
HDAC10 Q969S8 12/20 0.51
HDAC11 Q96DB2 12/20 0.51
HDAC8 Q9BY41 11/20 0.51
HDAC6 Q9UBN7 11/20 0.51
HDAC4 P56524 10/20 0.51
HDAC7 Q8WUI4 10/20 0.51
HDAC9 Q9UKV0 10/20 0.51
HDAC5 Q9UQL6 10/20 0.51
FAAH O00519 3/20 0.44
CES1 P23141 3/20 0.44
FOLH1 Q04609 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NCOR1 O75376 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11595736 0.80 L3MBTL1 (0.42) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL11598693 0.80 HDAC1 (0.42) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL8939158 0.70 KCNN4 (0.48) CES1MAPT
SCHEMBL8939183 0.69 ALDH1A1 (0.49)
Chlorobenzene SCHEMBL28101923 0.69 FOLH1 (0.59) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL8939163 0.69 KCNN4 (0.44) L3MBTL1LMNA
SCHEMBL13868873 0.69 KCNN4 (0.47) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL29679704 0.69 KCNN4 (0.47) MAPT
SCHEMBL13865461 0.69 KCNN4 (0.47) HDAC1HDAC2HDAC3HDAC10HDAC11
SCHEMBL13828216 0.69 OPRM1 (0.55) HDAC1HDAC2HDAC3HDAC10HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127797-A1 PRODRUG COMPRISING A DRUG-LINKER CONJUGATE ASCENDIS PHARMA A/S (DK) 2025-04-24 US disclosed
US-20240041897-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA GMBH (DE) 2024-02-08 US disclosed
US-20220331334-A1 Prodrug Comprising a Drug-Linker Conjugate ASCENDIS PHARMA A/S (DK) 2022-10-20 US disclosed
EP-3981761-A2 INTERMEDIATES FOR PRODRUGS Ascendis Pharma A/S (DK) 2022-04-13 EP disclosed
EP-2596805-B1 Prodrug comprising a drug-linker conjugate ASCENDIS PHARMA AS (DK) 2021-10-27 EP disclosed
US-20200046725-A1 Prodrug Comprising a Drug Linker Conjugate ASCENDIS PHARMA A/S (DK) 2020-02-13 US disclosed
EP-2237799-B1 PRODRUG COMPRISING A SELF-CLEAVABLE LINKER ASCENDIS PHARMA AS (DK) 2019-04-10 EP disclosed
US-20170100490-A1 Prodrug Comprising a Drug Linker Conjugate ASCENDIS PHARMA A/S (DK) 2017-04-13 US disclosed
US-20150057221-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2015-02-26 US disclosed
US-8906847-B2 Prodrug comprising a drug linker conjugate ASCENDIS PHARMA A/S (DK) 2014-12-09 US disclosed
EP-2596805-A1 Prodrug comprising a drug linker conjugate Ascendis Pharma A/S (DK) 2013-05-29 EP disclosed
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2011-03-03 US disclosed
EP-2237799-A2 PRODRUG COMPRISING A SELF-CLEAVABLE LINKER Ascendis Pharma AS (DK) 2010-10-13 EP disclosed
WO-2009095479-A2 PRODRUG COMPRISING A SELF-CLEAVABLE LINKER ASCENDIS PHARMA AS (DK) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150057221-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 HDAC1 437/4885HDAC2 795/4885HDAC3 445/4885
US-20170100490-A1 Prodrug Comprising a Drug Linker Conjugate H1-0, H1-3, H1-2 HDAC1 437/4885HDAC2 795/4885HDAC3 445/4885
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 HDAC1 439/4885HDAC2 794/4885HDAC3 444/4885
US-20200046725-A1 Prodrug Comprising a Drug Linker Conjugate H1-0, H1-3, H1-2 HDAC1 439/4885HDAC2 792/4885HDAC3 446/4885
US-20240041897-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 HDAC1 437/4885HDAC2 795/4885HDAC3 445/4885
US-20220331334-A1 Prodrug Comprising a Drug-Linker Conjugate H1-0, H1-3, DLST HDAC1 561/4885HDAC2 893/4885HDAC3 579/4885
US-20250127797-A1 PRODRUG COMPRISING A DRUG-LINKER CONJUGATE H1-0, H1-3, DLST HDAC1 561/4885HDAC2 893/4885HDAC3 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.